CSBR: Champions Oncology Price/Earnings to Growth Multiple

Symbol and logo of brand Champions Oncology Corp (CSBR)

Champions Oncology develops personalized therapy through PDX models, although global conflicts and trade barriers occasionally complicate the cross-border logistics of biomaterials. The history of P/E to growth rate ratios demonstrates the market valuation of the asset, where 0.00 captures the magnitude of this parameter. Meanwhile, the humanitarian status of medicine in the US minimizes political pressure, ensuring a stable financial backdrop.

Price/Earnings to Growth Ratio: Champions Oncology Inc (CSBR) for 07/04/2022 - 11/16/2026

Analytical breakdowns for Champions Oncology Inc (CSBR)

General company analysis:Champions Oncology Corp, CSBR
Mass-produced product of Champions Oncology, Inc.

Geopolitical instability and trade barriers are complicating the cross-border logistics of biomaterials for Champions Oncology (CSBR), creating risks for expansion rates. The P/E ratio relative to revenue growth rates is used to assess these processes. A value below one signals that the asset is undervalued relative to its growth dynamics. This method allows for the effective balancing of risk and return in long-term investing. By analyzing the PEG ratio for relative undervaluation, an investor can promptly identify the stock's growth potential.

Competing companies

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple